Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

被引：0

作者：

Blauvelt, Andrew ^{[11
]}

Armstrong, April ^{[1
]}

Merola, Joseph F. ^{[2
]}

Strober, Bruce ^{[3
,4
,5
]}

de Cuyper, Dirk ^{[6
]}

Peterson, Luke ^{[7
]}

Davies, Owen ^{[8
]}

Stark, Jeffrey L. ^{[9
]}

Lebwohl, Mark ^{[10
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Univ Calif Los Angeles UCLA, Los Angeles, CA USA

[3] UT Southwestern Med Ctr, Div Rheumatol, Dept Dermatol, Dallas, TX USA

[4] UT Southwestern Med Ctr, Dept Med, Div Rheumatol, Dallas, TX USA

[5] Yale Univ, Dept Dermatol, New Haven, CT USA

[6] Cent Connecticut Dermatol Res, Cromwell, CT USA

[7] UCB Pharm, Brussels, Belgium

[8] UCB Pharm, Morrisville, NC USA

[9] UCB Pharm, Slough, England

[10] UCB Pharm, Smyrna, GA USA

[11] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 01期

关键词：

bimekizumab; clinical trial; depression; eC-SSRS; long-term; mental health; PHQ-9; plaque; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; MULTICENTER; BRODALUMAB; DEPRESSION; USTEKINUMAB; SUICIDALITY; EFFICACY; VALIDITY; ANXIETY;

D O I：

10.1016/j.jaad.2024.02.039

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: Patients with psoriasis have increased risk of suicidal ideation and behavior (SIB) and depression. Bimekizumab, a biologic that inhibits interleukin (IL)-17A and IL-17F, received Food and Drug Administration approval in 2023 for moderate to severe plaque psoriasis, following 2021 European Medicines Agency approval. Objective: To report SIB and depression in patients with moderate to severe psoriasis treated in bimekizumab clinical trials. Methods: Mental health changes, including neuropsychiatric events, were actively monitored across 9 bimekizumab clinical trials in psoriasis phase 2/3 trials. The patient-reported electronic Columbia-Suicide Severity Rating Scale (measuring SIB) and Patient Health Questionnaire-9 (measuring depression) were administered, monitored by an independent Neuropsychiatric Adjudication Committee. Results: Throughout 7166 patient-years (PY) of bimekizumab exposure, the adjudicated SIB rate was 0.13/ 100PY; SIB ranges for the general psoriasis population and patients receiving anti-IL-17A/anti-IL-23

引用

页码：72 / 81

页数：10

共 50 条

[1] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
Gordon, Kenneth B.
Langley, Richard G.
Warren, Richard B.
Okubo, Yukari
Gold, Linda Stein
Merola, Joseph F.
Peterson, Luke
Wixted, Krista
Cross, Nancy
Deherder, Delphine
Thaci, Diamant
JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
[2] Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
Wang, Yuqian
Li, Sheng
Bai, Juan
Cai, Xiaoxuan
Tang, Shunli
Lin, Peiyi
Sun, Qingmiao
Qiao, Jianjun
Fang, Hong
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14
[3] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial
Blauvelt, Andrew
Wu, Jashin J.
Reich, Kristian
Gooderham, Melinda
Lebwohl, Mark
White, Katy
Cross, Nancy
Cioffi, Christopher
Papp, Kim A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB139 - AB139
[4] Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
Gordon, Kenneth B.
Langley, Richard G.
Warren, Richard B.
Okubo, Yukari
Rosmarin, David
Lebwohl, Mark
Peterson, Luke
Madden, Cynthia
de Cuyper, Dirk
Davies, Owen
Thaci, Diamant
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (04) : 477 - 485
[5] Bimekizumab in patients with moderate-to-severe plaque psoriasis by bodyweight: pooled results from phase III trials
Pinter, A.
Strober, B.
Rosmarin, D.
Gisondi, P.
Vanvoorden, V.
Peterson, L.
Madden, C.
de Cuyper, D.
Warren, R.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E48 - E49
[6] Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials
Lebwohl, Mark
Merola, Joseph F.
Strober, Bruce
Armstrong, April
Yoshizaki, Ayumi
Gisondi, Paolo
Szilagyi, Balint
Peterson, Luke
de Cuyper, Dirk
Cross, Nancy
Davies, Owen
Gottlieb, Alice B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (02) : 281 - 289
[7] Bimekizumab efficacy and safety through 2 years in patients with moderate to severe plaque psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Penas, Pablo Fernandez
Gordon, Kenneth B.
Armstrong, April W.
Lebwohl, Mark
Blauvelt, Andrew
Paul, Carle
Wang, Maggie
Vanvoorden, Veerle
Madden, Cynthia
Gomez, Natalie Nunez
Deherder, Delphine
Thaci, Diamant
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 20 - 20
[8] Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
Blauvelt, Andrew
Tada, Yayoi
Iversen, Lars
Mrowietz, Ulrich
Lebwohl, Mark
Wang, Maggie
Vanvoorden, Veerle
Cullen, Eva
Staelens, Fabienne
Papp, Kim A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB140 - AB140
[9] Incidence of cardiovascular events in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: pooled analysis from a phase 2 and two phase 3 trials
Bissonnette, R.
Fernandez-Penas, P.
Puig, L.
Peserico, A.
Fumero, E.
Mendelsohn, A.
Rozzo, S.
Menter, A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 46 - 47
[10] Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial
Reich, Kristian
Merola, Joseph F.
Elewski, Boni
Papp, Kim A.
Puig, Luis
Rich, Pheobe
Cioffi, Christopher
Cullen, Eva
Peterson, Luke
Gottlieb, Alice B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB70 - AB70

← 1 2 3 4 5 →